Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-12
2010-06-01
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S279000
Reexamination Certificate
active
07728003
ABSTRACT:
The invention addresses the current need for selective and potent protein tyrosine kinase inhibitors by providing potent inhibitors of c-fms kinase. The invention is directed to the novel compounds of Formula I:or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof, wherein: W, A, Y, n, Z, and R102are described in the specification.
REFERENCES:
patent: 4556709 (1985-12-01), Grohe et al.
patent: 2005/0049274 (2005-03-01), Wall et al.
patent: 0014390 (1980-08-01), None
patent: 0787726 (1997-08-01), None
patent: 09221424 (1997-08-01), None
patent: WO 96/34867 (1996-11-01), None
patent: WO 99/09030 (1999-02-01), None
patent: WO 01/70741 (2001-09-01), None
patent: WO 2005/009967 (2005-02-01), None
patent: WO 2007/033232 (2007-03-01), None
Huff, Joel R., “HIV Protease: A Novel Chemotherapeutic Target for AIDS,” Journal of Medicinal Chemistry, vol. 34, No. 8, Aug. 1991, pp. 2305-2314.
Cancer and Metastasis Reviews (1998), 17(1), 91-106.
Science (1999), vol. 286, 531-537.
Cecil Textbook of Medicine, 20thedition (1996), vol. 2, pp. 2050-2057.
Cecil Textbook of Medicine, 20thEdition (1996), vol. 2, pp. 1992-1996.
FDA mulls drug to slow late-stage Alzheimer's [online], [retrieved on Sep. 23, 2003]. Retrived from the internet, URL<http://www.cnn.com/2003/HEALTH/conditions/09/24/alzheimers.drug.ap/index.html>.
Byrn et al., Solid-State Chemistry of Drugs, Second Edition, 1999, pp. 233-247.
PCT International Search Report, dated Feb. 2, 2007, for PCT Int'l. Appln. No. PCT/US2006/035421.
Abstract, “Anti-neoplastic agent effective against solid tumours and leukaemia—comprising 7-substituted 1-thiazolyl-1, 8-naphthyridine derivative, showing high safety”, Database WPI Week 199747, Derwent Publications Ltd., London, GB, AN 1997-506304, Appln. No. JP19960351948, filed Dec. 10, 1996.
Desjarlais Renee L.
Huang Hui
Huaping Hu
Player Mark R.
Anderson Rebecca L
Janssen Pharmaceutica N.V.
LandOfFree
5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4246294